Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial

Covariate adjusted reanalysis of the I-Preserve trial

(2020) João Pedro Ferreira et al.   Clinical Research in Cardiology

Spironolactone dose in Heart Failure with Preserved Ejection Fraction: findings from TOPCAT

(2020) João Pedro Ferreira et al.   EUROPEAN JOURNAL OF HEART FAILURE

Low serum potassium levels and diabetes - An unfavorable combination in patients with heart failure and preserved ejection fraction

(2020) Roza Badr Eslam et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Abnormalities of Potassium in Heart Failure

(2020) João Pedro Ferreira et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF

(2020) Karola S. Jering et al.   JACC-Heart Failure

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments

(2019) Faiez Zannad et al.   EUROPEAN HEART JOURNAL SUPPLEMENTS

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

(2019) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients

(2018) Taiki Nishihara et al.   AMERICAN JOURNAL OF HYPERTENSION

Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

(2018) Csaba P Kovesdy et al.   EUROPEAN HEART JOURNAL

Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial

(2018) Akshay S. Desai et al.   JOURNAL OF CARDIAC FAILURE

Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction

(2018) Gianluigi Savarese et al.   JACC-Heart Failure

Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension

(2017) Csaba P. Kovesdy et al.   Journal of the American Society of Hypertension

How Dangerous Is Hyperkalemia?

(2017) John R. Montford et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction

(2017) Scott D. Solomon et al.   JACC-Heart Failure

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

(2017) Akshay S. Desai et al.   JAMA Cardiology

Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

(2017) Julio Núñez et al.   CIRCULATION

A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis

(2016) Nicolas Girerd et al.   EUROPEAN JOURNAL OF HEART FAILURE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease

(2013) Hsiao-Han Wang et al.   PLoS One

Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals

(2012) Elena Ramírez et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Serum Potassium Levels and Mortality in Acute Myocardial Infarction

(2012) Abhinav Goyal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION